Akari Therapeutics has appointed David Horn Solomon as its new chief executive officer, a role that will see him take the helm of the biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.
Ray Prudo, Akari’s executive chairman, said: “I am very pleased that David will be joining Akari and that we have been successful in attracting a person of his calibre, with over 20 years of leadership experience in the biotechnology field.
“David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by Sanofi.”
His other roles have included CEO at Bionor Pharma and most recently he was at Nordic healthcare investment group Sund Capital where he was a managing partner.
Solomon, who will be based at the group’s headquarters in New York, said: “I am excited by Akari’s growing and diversified discovery platform and its clinical programmes in the complement mediated diseases.
“Akari is building momentum in its research programmes and this is a hugely exciting time to join and help advance its products.”